Search Results - "Mixson, L. A."

p53 +/- Hemizygous Knockout Mouse: Overview of Available Data by Storer, Richard D., French, John E., Haseman, Joseph, Hajian, Gerald, Legrand, Edmund K., Long, Gerald G., Mixson, Lori A., Ochoa, Ricardo, Sagartz, John E., Soper, Keith A.

“…The performance of the p53 +/- transgenic (knockout) mouse model was evaluated through review of the data from 31 short-term carcinogenicity studies with 21…”
Get full text

In vitro Activity of Ertapenem against Common Clinical Isolates in Relation to Human Pharmacokinetics by Friedland, I., Mixson, L.A., Majumdar, A., Motyl, M., Woods, G.L.

“…The In vitro activity of ertapenem against bacterial pathogens isolated from patients with moderate to severe complicated intra-abdominal, complicated…”
Get full text

Mapping of hKCa3 to chromosome 1q21 and investigation of linkage of CAG repeat polymorphism to schizophrenia by AUSTIN, C. P, HOLDER, D. J, MA, L, MIXSON, L. A, CASKEY, C. T

“…CAG trinucleotide polymorphisms in the neuronal small conductance calcium-activated potassium channel gene hKCa3 have been reported to be associated with…”
Get full text

Adaptation of the WHO guideline for residual DNA in parenteral vaccines produced on continuous cell lines to a limit for oral vaccines by Lebron, J A, Troilol, P J, Pacchione, S, Griffiths, T G, Harper, L B, Mixson, L A, Jackson, B E, Michna, L, Barnum, A B, Denisova, L, Johnson, C N, Maurer, K L, Morgan-Hoffman, S, Niu, Z, Roden, D F, Wang, Z, Wolf, J J, Hamilton, T R, Laux, K M, Soper, K A, Ledwith, B J

“…Although there is a WHO guidance for a limit on residual DNA for parenterally administered vaccines produced on continuous cell lines, there is no…”
Get more information

Short-term metabolic effects of prednisone administration in healthy subjects by Kauh, E. A., Mixson, L. A., Shankar, S., McCarthy, J., Maridakis, V., Morrow, L., Heinemann, L., Ruddy, M. K., Herman, G. A., Kelley, D. E., Hompesch, M.

“…Aims: Supraphysiologic glucocorticoid activity is well established to cause impaired glucose tolerance and insulin resistance, yet no study has evaluated…”
Get full text

Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats by Schaefer, William H, Lawrence, Jeffery W, Loughlin, Amy F, Stoffregen, Dana A, Mixson, Lori A, Dean, Dennis C, Raab, Conrad E, Yu, Nathan X, Lankas, George R, Frederick, Clay B

“…As a class, hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors can potentially cause skeletal myopathy. One statin, cerivastatin, has recently…”
Get full text

Use of surrogate antimicrobial agents to predict susceptibility to ertapenem by Friedland, Ian R., Isaacs, Robin, Mixson, Lori A., Motyl, Mary, Woods, Gail L.

“…Broth or agar dilution susceptibility test results for Enterobacteriaceae (11,775 strains), anaerobes (2888 strains), staphylococci (2206 strains), Haemophilus…”
Get full text